CSTL icon

Castle Biosciences

29.57 USD
-2.31
7.25%
At close Updated Feb 27, 4:00 PM EST
Pre-market
After hours
30.10
+0.53
1.79%
1 day
-7.25%
5 days
2.78%
1 month
-30.98%
3 months
-25.98%
6 months
32.72%
Year to date
-23.27%
1 year
16.97%
5 years
-63.96%
10 years
38.18%
 

About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Employees: 823

0
Funds holding %
of 8,010 funds
0
Analysts bullish %
of 5 analysts
0
Positive news %
of 9 articles
Price charts implemented using Lightweight Charts™